Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436228 · ClinicalTrials.gov registry record
To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 32
- Enrollment target
NCT00436228: Completed study, sponsored by GlaxoSmithKline.
NCT00436228 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 32 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00436228 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections. The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate the safety of each of the four formulations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-02 |
What the finished NCT00436228 record still lists
NCT00436228 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00436228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00436228 about?
NCT00436228 is a clinical study titled "To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug". SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections. The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate the safety of each of the four formulations
What is the current status of trial NCT00436228?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2006-11. Estimated completion is 2007-02.
Who is sponsoring clinical trial NCT00436228?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia